New Nanomaterials and Techniques for Tumor-targeted Systems

r huang,y wang
DOI: https://doi.org/10.1007/978-981-15-5159-8
2020-01-01
Abstract:The ultimate goal of cancer nanomedicine is to specifically increase the drug accumulation in tumor and reduce side effects. Although nanomedicine has made great progress in recent decades, its delivery efficacy is still suboptimal, which hinders its clinical translation. Currently, most drug delivery vehicles are delivered by systemic administration, and physiological barriers prevent effective accumulation of nanomedicine at the tumor site. These nanocarriers must reach the tumor tissue after the long journey in blood circulation, then access to tumor cells deep inside the tumor by overcoming the tumor tissue barrier, and finally kill the tumor cells after entering the cell. Successful design of nanocarriers must fully consider the existing delivery barriers in order to achieve better therapeutic efficacy. This chapter summarizes obstacles experienced by nanomedicine from the site of injection and the site of action as well as exemplifies typical strategies for overcoming these barriers, hopefully providing insights into the design of more effective nanomedicine.
What problem does this paper attempt to address?